Opinion|Videos|February 3, 2025
Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection
Panelists discuss how VMAT2 inhibitors' most commonly reported adverse effects include somnolence, fatigue, and mild parkinsonism symptoms, which can typically be managed through dose adjustments and careful titration strategies, while noting these side effects are generally less severe than those of older treatments and rarely lead to discontinuation when patients are properly monitored and educated about expectations.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- What adverse effects are commonly reported with VMAT2 inhibitors, and how do they affect treatment decisions?
Advertisement
Related to this article
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
5